NIH Trial: Gilead’s Drug Works Best in COVID Patients on Oxygen

NIH Trial: Gilead’s Drug Works Best in COVID Patients on Oxygen
An ampule of remdesivir is pictured during a news conference at the University Hospital Eppendorf (UKE) in Hamburg, Germany, April 8, 2020. Ulrich Perrey/Reuters
Reuters
Updated:

The U.S. National Institutes of Health (NIH) on Friday said that data from its trial of Gilead Sciences Inc’s remdesivir show that the drug offers the most benefit for COVID-19 patients who need extra oxygen but do not require mechanical ventilation.

The peer-reviewed data was published in the New England Journal of Medicine.